Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL
2009-009256-20Phase 3Terminated
- Sponsor
- GSK
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in diffuse large B-cell lymphoma (DLBCL) comparing Ofatumumab plus salvage chemotherapy (O-chemo) with Rituximab plus salvage chemotherapy (R-chemo) (2 arms). Primary endpoint: Progression-free survival. Started Sep 2009; status: terminated.
02
Drugs
ofatumumabrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2009-009256-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009256-20.